Press Archive - Arriello

Medical cannabis in Europe: a compelling opportunity

Medical cannabis in Europe is not covered by a harmonised regulatory framework. However, Arriello director of drug safety, Peter Kohut, argues that this should not deter pharma companies from pursuing this increasingly attractive opportunity.

The Biosimilars Opportunity – Driving Access to Treatment in Europe

Gabriela Marton, Regulatory Affairs Director and Quality Director at Arriello, highlights EU regulatory challenges and calls for policy changes and education to maximize the opportunity for biosimilars to enhance patient outcomes.

Navigating the European Market for Medical Cannabis

There is considerable variation in the regulatory approach to medical cannabis between European countries. Yet, despite the complexity, there are clear routes to market, reports Peter Kohut.

Why aren’t more companies automating PV data capture?

Why are Safety & Pharmacovigilance departments lagging in their application of smart technology, when the pressures on pharmaceutical organisations to capture, sift and process real-world adverse event data are vast, asks John Price, a life sciences regulatory and safety consultant and advisor to Arriello.

The challenges of delivering medicinal information online.

In the light of new ePI guidelines in Europe for medicinal products, Irena Milobratovic, senior regulatory affairs manager at Arriello, considers the benefits and challenges associated with providing current product and safety information to patients and healthcare professionals via the web.